Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT. Stordal B, et al. Among authors: farrelly a. Mol Oncol. 2013 Jun;7(3):567-79. doi: 10.1016/j.molonc.2012.12.007. Epub 2013 Jan 31. Mol Oncol. 2013. PMID: 23415752 Free PMC article.
Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing.
Grimm C, Fischer A, Farrelly AM, Kalachand R, Castiglione R, Wasserburger E, Hussong M, Schultheis AM, Altmüller J, Thiele H, Reinhardt HC, Hauschulz K, Hennessy BT, Herwig R, Lienhard M, Buettner R, Schweiger MR. Grimm C, et al. Among authors: farrelly am. J Mol Diagn. 2019 Mar;21(2):198-213. doi: 10.1016/j.jmoldx.2018.10.007. Epub 2018 Dec 19. J Mol Diagn. 2019. PMID: 30576872 Free article.
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.
Toomey S, Carr A, Mezynski MJ, Elamin Y, Rafee S, Cremona M, Morgan C, Madden S, Abdul-Jalil KI, Gately K, Farrelly A, Kay EW, Kennedy S, O'Byrne K, Grogan L, Breathnach O, Morris PG, Eustace AJ, Fay J, Cummins R, O'Grady A, Kalachand R, O'Donovan N, Kelleher F, O'Reilly A, Doherty M, Crown J, Hennessy BT. Toomey S, et al. Among authors: farrelly a. J Transl Med. 2020 Feb 22;18(1):99. doi: 10.1186/s12967-020-02273-4. J Transl Med. 2020. PMID: 32087721 Free PMC article.
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.
Kalachand RD, O'Riain C, Toomey S, Carr A, Timms KM, O'Toole S, Madden S, Bates M, O'Leary JJ, Gleeson N, O'Donnell D, Grogan L, Breathnach O, Farrelly A, Stordal B, Hennessy BT. Kalachand RD, et al. Among authors: farrelly a. Obstet Gynecol Sci. 2020 Sep;63(5):643-654. doi: 10.5468/ogs.20033. Epub 2020 Sep 2. Obstet Gynecol Sci. 2020. PMID: 32872764 Free PMC article.
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".
Keegan NM, Furney SJ, Walshe JM, Gullo G, Kennedy MJ, Smith D, McCaffrey J, Kelly CM, Egan K, Kerr J, Given M, O'Donovan P, Hernando A, Teiserskiene A, Parker I, Kay E, Farrelly A, Carr A, Calzaferri G, McDermott R, Keane MM, Grogan L, Breathnach O, Morris PG, Toomey S, Hennessy BT. Keegan NM, et al. Among authors: farrelly a. Cancers (Basel). 2021 Mar 11;13(6):1225. doi: 10.3390/cancers13061225. Cancers (Basel). 2021. PMID: 33799597 Free PMC article.
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ, Farrelly AM, Cremona M, Carr A, Morgan C, Workman J, Armstrong P, McAuley J, Madden S, Fay J, Sheehan KM, Kay EW, Holohan C, Elamin Y, Rafee S, Morris PG, Breathnach O, Grogan L, Hennessy BT, Toomey S. Mezynski MJ, et al. Among authors: farrelly am. J Transl Med. 2021 May 1;19(1):184. doi: 10.1186/s12967-021-02842-1. J Transl Med. 2021. PMID: 33933113 Free PMC article.
BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
Cremona M, Vandenberg CJ, Farrelly AM, Madden SF, Morgan C, Kalachand R, McAlpine JN, Toomey S, Huntsman DG, Grogan L, Breathnach O, Morris P, Carey MS, Scott CL, Hennessy BT. Cremona M, et al. Among authors: farrelly am. Br J Cancer. 2022 Aug;127(3):488-499. doi: 10.1038/s41416-022-01823-5. Epub 2022 Apr 30. Br J Cancer. 2022. PMID: 35501389 Free PMC article.
Bone morphogenetic protein 3 controls insulin gene expression and is down-regulated in INS-1 cells inducibly expressing a hepatocyte nuclear factor 1A-maturity-onset diabetes of the young mutation.
Bonner C, Farrelly AM, Concannon CG, Dussmann H, Baquié M, Virard I, Wobser H, Kögel D, Wollheim CB, Rupnik M, Byrne MM, König HG, Prehn JH. Bonner C, et al. J Biol Chem. 2011 Jul 22;286(29):25719-28. doi: 10.1074/jbc.M110.215525. Epub 2011 May 31. J Biol Chem. 2011. PMID: 21628466 Free PMC article.
39 results